Wayne Koberstein
-
Companies To Watch: Hummingbird Bioscience
3/1/2023
Hummingbird Bioscience is joining the forces of computational and systems biology to fight cancer and autoimmune disease.
-
The Neo CEO
3/1/2023
Lex Rovner founded her company with support from academic scientists and has headed it since it opened for business in 2018. At that time, she had no prior experience as a company founder or as a CEO.
-
Scientist-Founders Reshape The Bio Biz
2/1/2023
Recently, it seems, new scientist-leaders have emerged whose backgrounds and acquired knowledge begin in science but grow to encompass business as well. Mammoth Biosciences is building, and betting, on such a model.
-
Companies To Watch: Corner Therapeutics
2/1/2023
Corner Therapeutics is focused on discovering new small molecules that could mimic the body’s natural immune response to generate the robust T-cell response.
-
Companies To Watch: Ocelot Bio
1/3/2023
Ocelot Bio is focusing a single drug on multiple complications of end-stage liver disease.
-
Biopharma Public Opinion, Pricing, Politics
12/1/2022
Biopharma sustainability will require the industry not shy from public opinion, but meet it head on. To win short-term battles, however impressively as with creation of the COVID vaccines, may not be enough to secure total victory.
-
Companies To Watch: iTolerance
11/1/2022
iTolerance is dedicated to curing diabetes and other conditions by inducing local immune tolerance in implantation.
-
Pioneering In-House, Continuous Manufacturing
11/1/2022
Patricia Hurter of Lyndra Therapeutics believes having an in-house continuous manufacturing capability delivers the flexibility, speed, and reliability needed for development and production of those long-acting drugs.
-
Companies To Watch: CytoAgents
10/3/2022
CytoAgents is combatting the broad areas of disease stemming from a common cause: cytokine release syndrome.
-
The Discovering CEO
10/3/2022
In the current world of biopharma companies, the discovery function covers much more than hammering out new drug entities.